BioCentury | Jan 8, 2021
Product Development

Jan. 7 Quick Takes: Sarepta tumbles after hours on DMD miss; plus InnoCare, AstraZeneca, Astellas and Autolus

Sarepta microdystrophin gene therapy misses endpointShares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) fell 50% to $84.45 in after-hours trading after  microdystrophin gene therapy SRP-9001 missed the primary functional endpoint of improvement in NSAA total score compared to...
BioCentury | Dec 17, 2020
Finance

Dec. 16 Quick Takes: Neurogene raises $115M while BioAtla sees first-day pop; plus fundings for Atsena, MinervaX, Vivace, Arvinas

Megaround for gene therapy play NeurogeneNeurogene Inc. raised $115 million in a series B round led by EcoR1 Capital, with participation by existing investors Redmile Group, Samsara BioCapital and Cormorant Asset Management. New investors include...
BioCentury | Jul 18, 2020
Management Tracks

Genzyme vet Modur joins Zikani; plus Scholar Rock, Poseida, Ribon, Kiadis and more

Zikani Therapeutics Inc. hired Vijay Modur as chief scientific and medical officer. He was global project head in rare disease clinical development at the Genzyme unit of Sanofi (Euronext:SAN; NASDAQ:SNY). Zikani is developing ribosome modulating...
BioCentury | Sep 27, 2019
Company News

Management tracks: Neurogene, HomoShear, Hookipa, Passage Bio, Artios, EMD Serono, Novartis, Illumina, Precision and CureDuchenne

Neurogene Inc . hired Christine Mikail as president. She is a co-founder of neurology specialty pharma Neumentum Inc. and biotech consulting firm Ferndale Advisors. Neurogene is developing disease-modifying gene therapies for two monogenic, pediatric disorders in...
BioCentury | Apr 4, 2019
Translation in Brief

Promoting AAV vectors to safety

Companies looking to make AAVs safer for gene therapies may need to test the vectors' genomic cargo for toxicity, according to a new study from a Harvard and Hong Kong group. Adeno-associated viral (AAV) vectors...
BioCentury | Apr 4, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: March 2019

New Therapeutic Targets and Biomarkers: March 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during March. Therapeutic targets are defined as any protein, gene or other molecule...
BioCentury | Mar 15, 2019
Emerging Company Profile

Neurogene: Genes over ERT for monogenic CNS diseases

Neurogene is developing disease-modifying gene therapies for two monogenic, pediatric disorders in which enzyme replacement is not feasible or hasn't been explored. Aspartylglucosaminuria (AGU) is a lysosomal storage disorder caused by autosomal recessive AGA mutations...
BioCentury | Feb 16, 2019
Company News

Emerging company roundup: Passage, IFM, Grey Wolf, Culture

In a week that had a pair of innovative Chinese companies raise early venture rounds and a Bay Area company debut its digital biomanufacturing platform, the biggest series A round went to Philadelphia gene therapy...
BioCentury | Feb 15, 2019
Financial News

Neurogene raises $68.5M series A for neurological disease gene therapies

Neurogene Inc. (New York, N.Y.) raised $68.5 million in a series A round to fund development of its adeno-associated viral (AAV)-based gene therapies to treat rare neurological diseases. Samsara BioCapital, EcoR1 Capital, Cormorant Asset Management,...
BioCentury | Feb 12, 2019
Financial News

Neurogene raises $68.5M series A for neurological disease gene therapies

Neurogene Inc. (New York, N.Y.) raised $68.5 million in a series A round to fund development of its adeno-associated viral (AAV)-based gene therapies to treat rare neurological diseases. Samsara BioCapital, EcoR1 Capital, Cormorant Asset Management,...
Items per page:
1 - 10 of 494
BioCentury | Jan 8, 2021
Product Development

Jan. 7 Quick Takes: Sarepta tumbles after hours on DMD miss; plus InnoCare, AstraZeneca, Astellas and Autolus

Sarepta microdystrophin gene therapy misses endpointShares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) fell 50% to $84.45 in after-hours trading after  microdystrophin gene therapy SRP-9001 missed the primary functional endpoint of improvement in NSAA total score compared to...
BioCentury | Dec 17, 2020
Finance

Dec. 16 Quick Takes: Neurogene raises $115M while BioAtla sees first-day pop; plus fundings for Atsena, MinervaX, Vivace, Arvinas

Megaround for gene therapy play NeurogeneNeurogene Inc. raised $115 million in a series B round led by EcoR1 Capital, with participation by existing investors Redmile Group, Samsara BioCapital and Cormorant Asset Management. New investors include...
BioCentury | Jul 18, 2020
Management Tracks

Genzyme vet Modur joins Zikani; plus Scholar Rock, Poseida, Ribon, Kiadis and more

Zikani Therapeutics Inc. hired Vijay Modur as chief scientific and medical officer. He was global project head in rare disease clinical development at the Genzyme unit of Sanofi (Euronext:SAN; NASDAQ:SNY). Zikani is developing ribosome modulating...
BioCentury | Sep 27, 2019
Company News

Management tracks: Neurogene, HomoShear, Hookipa, Passage Bio, Artios, EMD Serono, Novartis, Illumina, Precision and CureDuchenne

Neurogene Inc . hired Christine Mikail as president. She is a co-founder of neurology specialty pharma Neumentum Inc. and biotech consulting firm Ferndale Advisors. Neurogene is developing disease-modifying gene therapies for two monogenic, pediatric disorders in...
BioCentury | Apr 4, 2019
Translation in Brief

Promoting AAV vectors to safety

Companies looking to make AAVs safer for gene therapies may need to test the vectors' genomic cargo for toxicity, according to a new study from a Harvard and Hong Kong group. Adeno-associated viral (AAV) vectors...
BioCentury | Apr 4, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: March 2019

New Therapeutic Targets and Biomarkers: March 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during March. Therapeutic targets are defined as any protein, gene or other molecule...
BioCentury | Mar 15, 2019
Emerging Company Profile

Neurogene: Genes over ERT for monogenic CNS diseases

Neurogene is developing disease-modifying gene therapies for two monogenic, pediatric disorders in which enzyme replacement is not feasible or hasn't been explored. Aspartylglucosaminuria (AGU) is a lysosomal storage disorder caused by autosomal recessive AGA mutations...
BioCentury | Feb 16, 2019
Company News

Emerging company roundup: Passage, IFM, Grey Wolf, Culture

In a week that had a pair of innovative Chinese companies raise early venture rounds and a Bay Area company debut its digital biomanufacturing platform, the biggest series A round went to Philadelphia gene therapy...
BioCentury | Feb 15, 2019
Financial News

Neurogene raises $68.5M series A for neurological disease gene therapies

Neurogene Inc. (New York, N.Y.) raised $68.5 million in a series A round to fund development of its adeno-associated viral (AAV)-based gene therapies to treat rare neurological diseases. Samsara BioCapital, EcoR1 Capital, Cormorant Asset Management,...
BioCentury | Feb 12, 2019
Financial News

Neurogene raises $68.5M series A for neurological disease gene therapies

Neurogene Inc. (New York, N.Y.) raised $68.5 million in a series A round to fund development of its adeno-associated viral (AAV)-based gene therapies to treat rare neurological diseases. Samsara BioCapital, EcoR1 Capital, Cormorant Asset Management,...
Items per page:
1 - 10 of 494